Connor Iapoce

A faster rate of visual field progression was observed among 37 glaucomatous eyes treated with anti-VEGF for nAMD compared with a control group of 4304 eyes without anti-VEGF.

Serious forms of cardiovascular diseases were observed to be connected to a specific form of AMD with subretinal drusenoid deposits.

The novel investigational complement C5 inhibitor is the only product for treatment of geographic atrophy to achieve two positive phase 3 pivotal trials with statistical significance.

The apolipoprotein E ε2/ε3/ε4 variant was associated with a significant linearly increasing trend for risk of AMD from ε4 to ε3 to ε2.

Insulin glargline-aglr is the second approved interchangeable biosimilar insulin product to insulin glargine indicated to improve glycemic control in patients with diabetes mellitus.

Difluprednate treatment after AGV implantation resulted in a similar IOP and fewer glaucoma medications compared with prednisolone acetate.

Similar visual and anatomical outcomes were observed through 1 year, despite fewer injections in the mandated quarterly treated group.

Anti-brolucizumab ADAs may be a risk factor for intraocular inflammation and retinal occlusive vasculitis in patients treated with brolucizumab.

Approximately 20 million individuals in the US were living with AMD in 2019, including 18.34 million with early-stage AMD and 1.49 million with late-stage AMD.

Greater glaucoma polygenic risk was associated with faster structural and functional progression in early POAG, despite individuals receiving more intensive treatment.

Intravitreal aflibercept, bevacizumab and ranibizumab were each associated with comparable significant decreases in RGCL thickness in nAMD.

The analysis additionally suggested the potential benefits of finerenone in the prevention of required ocular interventions.

At AHA 2022, Dr. Ray discusses the findings from the phase II open-label extension trial and highlights other important trial data for lipidologists.

A deep dive into exciting late-breaking trial data at AHA 2022, differences in chest pain guidelines, and bringing patient voice into clinical research.

A Q&A with Dr. Bonaca highlights new data on rivaroxaban for PAD and the late-breaking science at AHA 2022.

The trial achieved its primary efficacy endpoint of terminating PSVT with self-administered etripamil, using symptom-based optional repeat dosing.

The late-breaking findings suggest the potential prognostic benefit of highly purified EPA in patients with chronic CAD with a low EPA/AA ratio.

Over a six-month period, SGLT2 inhibition with empagliflozin did not change left ventricular structure or function compared with placebo in people without diabetes or significant heart failure.

Patients with early VA-ECMO use saw comparable outcomes to those who initially received conservative therapy for hemodynamic stabilization.

Education and place of birth contribute the most to the racial and ethnic differences observed in mean CVH score.

A single intravenous dose of NTLA-2001 significantly reduced abnormal levels of transthyretin in patients with ATTR amyloid cardiomyopathy, reports new data from AHA 2022.

Risk stratification in the emergency department led to a 12% lower risk of death from any cause or hospitalization for cardiovascular causes compared with usual care.

The late-breaking findings presented at AHA 2022 suggest the incidence of CV events was not lower among patients who received pemafibrate compared with those who received placebo.

National deaths from heart disease spiked in 2020 in the beginning of the COVID-19 pandemic, after an observed steady decline from 2010 to 2019.

Only 12% of people with CVD older than age 65 used wearable devices, despite estimates suggesting half of all people with CVD are older than age 65.

The 30-year analysis suggests a significantly higher risk associated with lead exposure and lower risk for particulate matter in the US than in the UK.

The need for repeat laser peripheral iridotomy was comparable in the study, at 10.0% in the nepafenac group compared to 15.4% in the bromfenac group.

High IOP variability was independently associated with retinal nerve fiber layer thinning rate in patients with glaucoma.

Genentech indicates faricimab-svoa achieved its primary endpoint of non-inferiority to aflibercept in RVO treatment in the phase 3 BALATON and COMINO trials.

The meta-analysis estimated a dry eye prevalence of 8.1% and MGD prevalence of 21.2%.